Abstract
Background Traditional Phase 1 trials often provide important drug development insights, which can be limited by ethical issues, costs, and lengthy timelines. Advancements in AI based simulations offer a potential avenue for mitigating these challenges. The present study used the aiHumanoid platform, specifically the upgraded DeepNEU database v8.1, to design and conduct a virtual Phase 1 trial, to assess the comparative efficacy and toxicity of standard chemotherapy with gemcitabine plus Taxol vs a combination of standard chemotherapy plus COTI-2 for treating Pancreatic Adenocarcinoma (PAC).
Methods Applying the updated DeepNEU database of 7267 genotypic and phenotypic concepts linked through 67491 relationships, the study used aiHumanoid simulations to predict outcomes from 30 virtual patients. Data from the standard chemotherapy arm and the standard treatment plus COTI2 arm were analyzed at 25%, 50%, 75%, and 100% of maximal dose. Estimates of efficacy and potential toxicities were based on a combination of the paired 2 tailed T test and Cohen’s d values as a true estimate of treatment effects.
Results The novel combined treatment regimen, especially at 100% dosage, showed medium to large treatment effects on the entire Pancreatic Adenocarcinoma disease profile. Notably, a significant decrease was observed in all disease profile components, bolstered by p-values less than 8.68E-5 and Cohen’s d values >=0.335. While evidence hinted at an increased bone marrow toxicity in the novel treatment arm, no individual organoid toxicity exceeded one standard deviation above predicted values. Importantly, COTI-2 treatment demonstrated a dose-dependent increase in p53 levels, significant at p < 0.006.
Conclusion This aiHumanoid’s virtual Phase 1 trial emphasizes the potential of computational simulations in the drug development process. Our findings indicate a promising treatment pathway combining COTI-2 with standard chemotherapy for Pancreatic Adenocarcinoma. Ongoing development and validation of the aiHumanoid based virtual Phase 1 clinical trial methodology is warranted.
Competing Interest Statement
The author, Dr. Wayne R. Danter was involved in the discovery, preclinical and early Phase 1 clinical development of COTI-2.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos